Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-4: Andexanet Alfa in Acute Major Bleeding
NCT02329327Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of andexanet alfa in Acute major hemorrhage, sponsored by Alexion Pharmaceuticals. Started Apr 2015; status: completed.
02
Drugs
andexanet alfa
03
Conditions
Acute major hemorrhage
Beyond the preview
Go deeper on NCT02329327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329327.